Data Insights

Tapotoclax by Amgen for Chronic Myelomonocytic Leukemia (CMML): Likelihood of Approval

Tapotoclax is under clinical development by Amgen and currently in Phase I for Chronic Myelomonocytic Leukemia (CMML). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Tapotoclax in Chronic Myelomonocytic Leukemia (CMML)

Data Insights

Tapotoclax by Amgen for Myelodysplastic Syndrome: Likelihood of Approval

Tapotoclax is under clinical development by Amgen and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Tapotoclax in Myelodysplastic Syndrome

Data Insights

Tapotoclax by Amgen for Refractory Multiple Myeloma: Likelihood of Approval

Tapotoclax is under clinical development by Amgen and currently in Phase I for Refractory Multiple Myeloma. According to GlobalData, Phase...

Data Insights

Tapotoclax by Amgen for Refractory Acute Myeloid Leukemia: Likelihood of Approval

Tapotoclax is under clinical development by Amgen and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData,...

Data Insights

Tapotoclax by Amgen for Relapsed Multiple Myeloma: Likelihood of Approval

Tapotoclax is under clinical development by Amgen and currently in Phase I for Relapsed Multiple Myeloma. According to GlobalData, Phase...

Data Insights

Tapotoclax by Amgen for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

Tapotoclax is under clinical development by Amgen and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to GlobalData,...